Literature DB >> 21889952

Overview of glutamatergic neurotransmission in the nervous system.

Mark J Niciu1, Benjamin Kelmendi, Gerard Sanacora.   

Abstract

This introductory article to the special edition on glutamate neurotransmission in neuropsychiatric disorders provides an overview of glutamate neurotransmitter system physiology and pharmacology. Glutamate was only relatively recently recognized as the major excitatory neurotransmitter in the mammalian brain, in part due to its ubiquitous nature and diverse metabolic roles within the CNS. The extremely high concentration of glutamate in brain tissue paired with its excitotoxic potential requires tight physiological regulation of extracellular glutamate levels and receptor signaling in order to assure optimal excitatory neurotransmission but limits excitotoxic damage. In order to achieve this high level of control, the system has developed a complex physiology with multiple regulatory processes modulating glutamate metabolism, release, receptor signaling, and uptake. The basic physiology of the various regulatory components of the system including the rich receptor pharmacology is briefly reviewed. Potential contributions from each of the system's components to the pathophysiology of neuropsychiatric illnesses are briefly discussed, as are the many new pharmacological targets for drug development provided by the system, especially as they pertain to the proceeding preclinical and clinical articles in this issue.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889952      PMCID: PMC3253893          DOI: 10.1016/j.pbb.2011.08.008

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  167 in total

1.  Kalirin, a cytosolic protein with spectrin-like and GDP/GTP exchange factor-like domains that interacts with peptidylglycine alpha-amidating monooxygenase, an integral membrane peptide-processing enzyme.

Authors:  M R Alam; R C Johnson; D N Darlington; T A Hand; R E Mains; B A Eipper
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

2.  Neuroligins mediate excitatory and inhibitory synapse formation: involvement of PSD-95 and neurexin-1beta in neuroligin-induced synaptic specificity.

Authors:  Joshua N Levinson; Nadège Chéry; Kun Huang; Tak Pan Wong; Kimberly Gerrow; Rujun Kang; Oliver Prange; Yu Tian Wang; Alaa El-Husseini
Journal:  J Biol Chem       Date:  2005-02-21       Impact factor: 5.157

Review 3.  Glutamate receptor dynamics in dendritic microdomains.

Authors:  Thomas M Newpher; Michael D Ehlers
Journal:  Neuron       Date:  2008-05-22       Impact factor: 17.173

4.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

5.  Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites.

Authors:  Robert T Fremeau; Kaiwen Kam; Tayyaba Qureshi; Juliette Johnson; David R Copenhagen; Jon Storm-Mathisen; Farrukh A Chaudhry; Roger A Nicoll; Robert H Edwards
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Homomeric and heteromeric ion channels formed from the kainate-type subunits GluR6 and KA2 have very small, but different, unitary conductances.

Authors:  J R Howe
Journal:  J Neurophysiol       Date:  1996-07       Impact factor: 2.714

7.  Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression.

Authors:  Beata Karolewicz; Katalin Szebeni; Tempestt Gilmore; Dorota Maciag; Craig A Stockmeier; Gregory A Ordway
Journal:  Int J Neuropsychopharmacol       Date:  2008-06-23       Impact factor: 5.176

8.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 9.  Roles and regulation of glutamate transporters in the central nervous system.

Authors:  R D O'Shea
Journal:  Clin Exp Pharmacol Physiol       Date:  2002-11       Impact factor: 2.557

10.  Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses.

Authors:  Sofia Papadia; Francesc X Soriano; Frédéric Léveillé; Marc-Andre Martel; Kelly A Dakin; Henrik H Hansen; Angela Kaindl; Marco Sifringer; Jill Fowler; Vanya Stefovska; Grahame McKenzie; Marie Craigon; Roderick Corriveau; Peter Ghazal; Karen Horsburgh; Bruce A Yankner; David J A Wyllie; Chrysanthy Ikonomidou; Giles E Hardingham
Journal:  Nat Neurosci       Date:  2008-03-23       Impact factor: 24.884

View more
  96 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Glutamate transporters in brain ischemia: to modulate or not?

Authors:  Weronika Krzyżanowska; Bartosz Pomierny; Magłorzata Filip; Joanna Pera
Journal:  Acta Pharmacol Sin       Date:  2014-03-31       Impact factor: 6.150

Review 3.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

Review 4.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 5.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors:  Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

Review 6.  SOX1 Is a Backup Gene for Brain Neurons and Glioma Stem Cell Protection and Proliferation.

Authors:  Kouminin Kanwore; Xiao-Xiao Guo; Ayanlaja Abiola Abdulrahman; Piniel Alphayo Kambey; Iqra Nadeem; Dianshuai Gao
Journal:  Mol Neurobiol       Date:  2021-01-22       Impact factor: 5.590

7.  A glutamate-dependent redox system in blood cells is integral for phagocytosis in Drosophila melanogaster.

Authors:  Jessica Tang; Ashley E Nazario-Toole; Elizabeth A Gonzalez; Aprajita Garg; Louisa P Wu
Journal:  Curr Biol       Date:  2013-11-07       Impact factor: 10.834

8.  Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.

Authors:  Xiaofei Zhang; Katsushi Kumata; Tomoteru Yamasaki; Ran Cheng; Akiko Hatori; Longle Ma; Yiding Zhang; Lin Xie; Lu Wang; Hye Jin Kang; Douglas J Sheffler; Nicholas D P Cosford; Ming-Rong Zhang; Steven H Liang
Journal:  ACS Chem Neurosci       Date:  2017-06-13       Impact factor: 4.418

9.  Regional Metabolic Patterns of Abnormal Postoperative Behavioral Performance in Aged Mice Assessed by 1H-NMR Dynamic Mapping Method.

Authors:  Taotao Liu; Zhengqian Li; Jindan He; Ning Yang; Dengyang Han; Yue Li; Xuebi Tian; Huili Liu; Anne Manyande; Hongbing Xiang; Fuqiang Xu; Jie Wang; Xiangyang Guo
Journal:  Neurosci Bull       Date:  2019-08-02       Impact factor: 5.203

Review 10.  Glial cells as therapeutic targets for smoking cessation.

Authors:  Mohit Kumar; Adewale Adeluyi; Erin L Anderson; Jill R Turner
Journal:  Neuropharmacology       Date:  2020-05-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.